Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Immunol Res. 2013 May;56(1):1–8. doi: 10.1007/s12026-012-8382-7

Figure 1.

Figure 1

Intravenous (i.v.) transfer of bone marrow-derived DCs inhibits EAE development. EAE was induced in mice via immunization with MOG/CFA. PBS and DC pulsed with MOG (0.1μM) (DC-MOG) or not(DC) were i.v. injected into EAE mice at days 11, 14 and 17 p.i (3×105 cells/ mouse/injection). EAE development with clinical score (A) from day 0 to day 30 p.i is shown. This experiment was repeated three times with similar results. Data represent the mean and SEM of EAE clinical score (n=3, t test, * P<0.05) in one experiment. Spleen cells were isolated from mice treated with DC-MOG, DC or PBS at day 30 and re-stimulated with MOG peptide (0.1 μM) and mouse IL-2 (1 ng/ml) for 5 days. The supernatant was collected to detect IFN-γ(B) and IL-10 (C) and IL-17A (D) by ELISA. The error bars shown in B, C and D represent mean and SD of the cytokine concentration in three independent experiments (n=3, t test, *P<0.05).